Skip to main content
. Author manuscript; available in PMC: 2023 Mar 2.
Published in final edited form as: Cancer Res. 2022 Sep 2;82(17):3158–3171. doi: 10.1158/0008-5472.CAN-22-0170

Figure 2. Palovarotene reduces PCa-induced bone formation and tumor growth in SCID mice.

Figure 2.

(A) C4-2b-BMP4 subcutaneous implantation. (B) Goldner Trichrome staining of C4-2b-BMP4 tumors quantified using ImageJ. (C) Tumor size measurement by BLI in mice with C4-2b-BMP4 tumors. (D) Tumor weight at the termination of the study. Control (n=5), Palo-treated (n=5). (E) TRAMP-BMP4 intrabone injection. (F) MicroCT of femurs with or without TRAMP-BMP4 tumors (left). Histology of TRAMP-BMP4-induced bone compared with the non-tumor bearing bone (middle). B(bone), T(tumor). Palo on bone mineral density of tumor-bearing femurs (right). (G) TRAMP-BMP4 tumor size by BLI. Control (n=7); Palo-treated (n=5). (H) MycCaP-BMP4 intrabone injection (left). X-Ray of osteoblastic bone response induced by MycCaP-BMP4 in femurs with or without Palo (middle) and relative intensity quantified by ImageJ (right). Blue arrows, tumor bearing bone in the control group. (I) MycCaP-BMP4 tumor size by BLI. Control (n=5); Palo-treated (n=5).